Mice exhibiting low Nectin-4 engagement post-treatment showed reduced tumor growth inhibition, regardless of dose, suggesting that target engagement itself may serve as a more reliable early biomarker of therapeutic efficacy than dose or Nectin-4 expression alone. Here, NECTIN4 is linked to neoplasm.